SCHEMBL5495206

SCHEMBL5495206

O=C(O)CC1CCCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 4/20 0.64
GABRA5 P31644 3/20 0.64
GABRB2 P47870 3/20 0.64
SLC6A11 P48066 3/20 0.64
SLC6A13 Q9NSD5 3/20 0.64
SLC6A12 P48065 2/20 0.64
GABRA1 P14867 2/20 0.64
GABRA4 P48169 2/20 0.64
GABRR1 P24046 1/20 0.64
CPN1 P15169 3/20 0.42
CPB2 Q96IY4 3/20 0.42
TSHR P16473 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRE P78334 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8131617 0.92 GABRA5 (0.60) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL44579 0.91 GABRA5 (0.75) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL1967312 0.89 GABRA5 (0.72) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL17275233 0.85 SLC6A12 (0.67) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL18828823 0.83 SLC6A1 (0.77) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL1225755 0.83 SLC6A1 (0.77) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL18828784 0.83 SLC6A1 (0.77) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL9820766 0.82 SLC6A12 (0.54) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL5050450 0.82 SLC6A1 (0.74) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
Hydrochloric Acid SCHEMBL22323200 0.82 SLC6A1 (0.74) SLC6A1GABRA5GABRB2SLC6A11SLC6A13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104619709-A Imidazopyridine derivatives as modulators of TNF activity UCB PHARMA SA 2015-05-13 CN disclosed
US-20070238721-A1 Highly Selective Novel Amidation Method TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-10-11 US disclosed
EP-1753752-A1 HIGHLY SELECTIVE NOVEL AMIDATION METHOD Takeda Pharmaceutical Company Limited (JP) 2007-02-21 EP disclosed
WO-2005121133-A1 HIGHLY SELECTIVE NOVEL AMIDATION METHOD TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238721-A1 Highly Selective Novel Amidation Method NAAA, CPS1, COASY SLC6A1 3877/4885GABRA5 2173/4885GABRB2 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.